Migraine Management (eBook, ePUB)

Redaktion: Swanson, Jerry W.; Matharu, Manjit

• Format: ePub

Produktbeschreibung

Migraine Management, Volume 196 covers the effective treatment of migraines, including different subtypes of migraines in different patient populations. The classification and diagnostic criteria of common and uncommon subtypes of migraine is explored in detail, including childhood variants. An in-depth analysis of the pharmacology of acute and prophylactic agents is presented, along with an evidence-based review of pharmacologic management. This includes recently developed CGRP monoclonal antibodies and non-peptide small molecule CGRP antagonists. Advances in neuromodulatory treatments, both noninvasive and implantable, are also critically reviewed.

Finally, specific treatment-related issues in pregnancy and lactation and childhood as well as the elderly are covered. Issues related to the diagnosis and management of vestibular migraine and the co-morbid disorder of persistent postural-perceptual dizziness is also explored.

• Summarizes evidence-based best treatment for migraines
• Differentiates treatment based on patient population, migraine type, and clinical setting
• Includes pharmacological, biobehavioral, and physical treatments
• Provides specialized treatments for children, the elderly, and pregnant patients

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science & Techn.
• Seitenzahl: 450
• Erscheinungstermin: 19. März 2024
• Englisch
• ISBN-13: 9780128234815
• Artikelnr.: 69895804

Inhaltsangabe

Section I. Migraine Management 1. Non-specific analgesics, combination
analgesics, and antiemetics 2. The 5-HT1B and 5-HT1D Agonists in Acute
Migraine Therapy: Ergotamine, dihydroergotamine, and the triptans 3. 5-HT1F
agonists 4. CGRP receptor antagonists (Gepants) 5. Preventive treatment of
migraine: Non-specific oral agents 6. OnabotulinumtoxinA: Discussion of the
evidence for effectiveness of OnabotulinumA and its place in chronic
migraine treatment 7. CGRP monoclonal antibodies and CGRP receptor
antagonists (Gepants) in migraine prevention 8. Nutraceuticals in migraine
9. Interventional treatments 10. Biobehavioral treatments of migraine 11.
Physical treatment of migraine 12. Neuromodulation in migraine Section II.
Guidelines 13. Evidence-based symptomatic treatment of migraine 14.
Evidence-based preventive treatment of migraine Section III. Special
Cases/Situations 15. Treatment in the emergency department 16. Special
considerations in migraine during pregnancy and lactation 17. Special
considerations in management of migraine in the elderly 18. Management of
medication overuse headache Section IV. Outcome Measures 19. Outcome
Measures for Migraine: Measuring the impact of migraine and results of
migraine treatment Section V. Diagnosis and Treatment of Other Migraine
Subtypes 20. Menstrually associated migraine 21. Hemiplegic migraine 22.
Migraine with brainstem aura 23. Retinal migraine 24. Vestibular migraine
and persistent postural perceptual dizziness 25. Status migrainosus 26.
Persistent aura, visual snow, and other visual symptoms 27. Migrainous
infarction 28. Migraine in children and adolescents: Assessment and
diagnosis 29. Management of migraine in children and adolescents Section
VI. Comorbidities of Migraine 30. Psychiatric comorbidities of migraine 31.
Relationship of migraine and other forms of chronic pain 32. Comorbidities
of migraine: Sleep disorders 33. The evolving concept of multimorbidity and
migraine Section VII. Future Directions 34. Healthcare disparities faced by
patients with migraine and potential mitigation strategies 35. Emerging and
future directions of migraine research and treatment